CXCR4, however, is expressed on immune cells suggesting that SDF-1/CXCR4-targeted anti-cancer therapy at the same time interferes with the immune response to cancers and cancer cells in e.g., circulation or micrometastases. This evidence concerns the gene CXCR4 and cancer.